aibioAethlon effects 1-for-5 reverse stock split effective July 31
Tickers AEMD
The split takes effect at 10:00 a.m. Eastern Time on July 31, 2026, and shares are expected to trade split-adjusted on August 4, 2026 under AEMD.
Key facts
- Company
- AETHLON MEDICAL INC (NASDAQ: AEMD)
- News type
- Listings
- Primary source
- AETHLON MEDICAL INC 8-K (2026-07-31)
Aethlon Medical, Inc. filed a Certificate of Change with the Nevada Secretary of State on July 30, 2026, authorizing a 1-for-5 reverse stock split of its common stock, according to a Form 8-K filed July 31, 2026. The split takes effect at 10:00 a.m. Eastern Time on July 31, 2026, under NRS Section 78.209.
Trading is expected to begin on a split-adjusted basis on The Nasdaq Capital Market when the market opens on August 4, 2026, under the existing symbol AEMD. The CUSIP number will change to 00808Y703. Computershare Transfer, Inc. is acting as transfer and exchange agent.
Why the company did it
The filing gives the reason as part of the company's overall capital-markets and operating plan, including dilution management and continued compliance with Nasdaq Listing Rule 5550(a)(2). The board approved the split under NRS Section 78.207, so the 8-K says no stockholder approval was required.
The mechanics
Each stockholder's shares become the number held before the split divided by five. No cash is paid for fractions. The company issues one whole share to any stockholder who would otherwise receive a fraction. Registered holders do not need to act.
Authorized and outstanding shares
Before the split the company was authorized to issue 100,000,000 shares of common stock. After the split it will be authorized to issue 20,000,000 shares. As of July 23, 2026, there were 3,249,569 shares outstanding, which the filing says will become approximately 649,914 shares after the split, subject to rounding. The authorized preferred shares are not affected.
The company says each stockholder's percentage ownership and voting power will remain virtually unchanged, apart from rounding. Options, warrants and convertible securities outstanding before the split will be adjusted.
The business behind the stock
Aethlon describes itself in its annual report as a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage investigational immunotherapeutic device that binds and removes enveloped viruses and extracellular vesicles from biological fluids. The FDA has granted the device Breakthrough Device designation for advanced or metastatic cancer that is unresponsive to or intolerant of standard-of-care therapy, and for life-threatening viruses not addressed with approved therapies. The 10-K says the device has been evaluated in human studies involving 173 treatment sessions in 44 patients.
The company is running a safety, feasibility and dose-finding trial in Australia in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy. The trial is designed to enroll approximately 9 to 18 participants, and the primary endpoint is safety. The annual report says the company completed the second cohort in March 2026 and that no serious adverse events or dose-limiting toxicities related to the device had been reported.
Financial position
The 10-K filed June 10, 2026 shows research and development expense of $1.9 million for the fiscal year ended March 31, 2026, against $2.2 million for fiscal 2025. The net loss was $7.2 million for fiscal 2026 and $13.4 million for fiscal 2025. Cash from operations was negative $7.0 million for fiscal 2026 and negative $7.6 million for fiscal 2025. Year-end cash and cash equivalents were $5.0 million at March 31, 2026, against $5.5 million a year earlier.
What the split does not fix
A reverse split changes the share count and not the business. The 3,249,569 shares outstanding on July 23, 2026 become approximately 649,914. The filing cites dilution management as a reason, which points to a company that has been issuing shares, and it ties the split to continued Nasdaq compliance. The board acted without a stockholder vote. The company still reports a net loss of $7.2 million and cash used in operations of $7.0 million for fiscal 2026. The device is investigational, the Australian trial is small and its primary endpoint is safety, and the sources show no efficacy results. The filing does not say whether the split will satisfy the listing rule.